Cargando…
Optimizing weight control in diabetes: antidiabetic drug selection
CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047980/ https://www.ncbi.nlm.nih.gov/pubmed/21437098 http://dx.doi.org/10.2147/DMSOTT.S11941 |
_version_ | 1782199113506357248 |
---|---|
author | Kalra, S Kalra, B Unnikrishnan, AG Agrawal, N Kumar, S |
author_facet | Kalra, S Kalra, B Unnikrishnan, AG Agrawal, N Kumar, S |
author_sort | Kalra, S |
collection | PubMed |
description | CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control. IMPLEMENTATION: Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.1. Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs. |
format | Text |
id | pubmed-3047980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-30479802011-03-23 Optimizing weight control in diabetes: antidiabetic drug selection Kalra, S Kalra, B Unnikrishnan, AG Agrawal, N Kumar, S Diabetes Metab Syndr Obes Evidence 2 Practice CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control. IMPLEMENTATION: Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.1. Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs. Dove Medical Press 2010-08-24 /pmc/articles/PMC3047980/ /pubmed/21437098 http://dx.doi.org/10.2147/DMSOTT.S11941 Text en © 2010 Kalra et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Evidence 2 Practice Kalra, S Kalra, B Unnikrishnan, AG Agrawal, N Kumar, S Optimizing weight control in diabetes: antidiabetic drug selection |
title | Optimizing weight control in diabetes: antidiabetic drug selection |
title_full | Optimizing weight control in diabetes: antidiabetic drug selection |
title_fullStr | Optimizing weight control in diabetes: antidiabetic drug selection |
title_full_unstemmed | Optimizing weight control in diabetes: antidiabetic drug selection |
title_short | Optimizing weight control in diabetes: antidiabetic drug selection |
title_sort | optimizing weight control in diabetes: antidiabetic drug selection |
topic | Evidence 2 Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047980/ https://www.ncbi.nlm.nih.gov/pubmed/21437098 http://dx.doi.org/10.2147/DMSOTT.S11941 |
work_keys_str_mv | AT kalras optimizingweightcontrolindiabetesantidiabeticdrugselection AT kalrab optimizingweightcontrolindiabetesantidiabeticdrugselection AT unnikrishnanag optimizingweightcontrolindiabetesantidiabeticdrugselection AT agrawaln optimizingweightcontrolindiabetesantidiabeticdrugselection AT kumars optimizingweightcontrolindiabetesantidiabeticdrugselection |